Impaired platelet thromboxane production in renal failure

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Patients with renal failure often exhibit impaired platelet function.
• Thromboxane B2 is a key mediator in platelet aggregation.

Purpose of the Study:

• To investigate the impact of renal failure on platelet aggregation and thromboxane B2 production.
• To determine the role of plasma factors and hemodialysis in uremic platelet dysfunction.

Main Methods:

• Assessed platelet aggregation and thromboxane B2 production in patients with renal failure and normal subjects.
• Compared responses in undialyzed/inadequately dialyzed versus adequately dialyzed patients.
• Incubated normal platelets with uremic platelet-poor plasma to identify causative factors.

Main Results:

• Platelet aggregation and thromboxane B2 production were significantly reduced in undialyzed or inadequately dialyzed patients.
• Adequate hemodialysis corrected the platelet defect in one patient.
• Uremic platelet-poor plasma induced defects in normal platelet aggregation and thromboxane synthesis.

Conclusions:

• A plasma factor in uremic patients may inhibit platelet thromboxane synthesis, contributing to platelet dysfunction.
• Adequate hemodialysis can potentially reverse the uremic platelet defect.